NAUTIKA1 Study: Preliminary Efficacy and Safety Data with Neoadjuvant Alectinib in Patients with Stage IBIII ALK plus NSCLC

被引：0
|
作者：
Lee, J. M. [1 ]
Toloza, E. M. [2 ,3 ]
Pass, H. I. [4 ]
Johnson, B. E. [5 ]
Heymach, J. V. [6 ]
Sholl, L. [7 ]
Saqi, A. [8 ]
Travis, W. D. [9 ]
Wistuba, I. [6 ]
Lin, J. [10 ]
Kris, M. G. [9 ]
Spira, A. I. [11 ,12 ]
Shu, C. A. [8 ]
Saltos, A. N. [13 ]
Ding, B. [14 ]
Schulze, K. [14 ]
Zhu, Q. [14 ]
Ngiam, C. [14 ]
Bara, I. [14 ]
Chaft, J. E. [9 ]
机构：
[1] UCLA, David Geffen Sch Med, Los Angeles, CA USA
[2] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
[3] Univ South Florida Hlth, Morsani Coll Med, Tampa, FL USA
[4] NYU Langone Med Ctr, New York, NY USA
[5] Dana Farber Canc Inst, Boston, MA 02115 USA
[6] MD Anderson Canc Ctr, Houston, TX USA
[7] Brigham & Womens Hosp, Boston, MA USA
[8] Columbia Univ, Med Ctr, New York, NY USA
[9] Mem Sloan Kettering Canc Ctr, New York, NY USA
[10] Univ Michigan, Med Sch, Ann Arbor, MI USA
[11] US Oncol Res, The Woodlands, TX USA
[12] Virginia Canc Specialists, Fairfax, VA USA
[13] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
[14] Genentech Inc, San Francisco, CA USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 11期
关键词：
alectinib; neoadjuvant; local-regional NSCLC;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P2.01-06
引用
收藏
页码：S297 / S298
页数：2
相关论文
共 50 条
  • [1] Phase II NAUTIKA1 Study of Targeted Therapies in Stage II-III NSCLC: Preliminary Data of Neoadjuvant Alectinib for ALK plus NSCLC
    Lee, J. M.
    Sepesi, B.
    Toloza, E. M.
    Lin, J.
    Pass, H. I.
    Johnson, B. E.
    Heymach, J. V.
    Johnson, M. L.
    Ding, B.
    Schulze, K.
    Zhu, Q.
    Ngiam, C.
    Brandao, E.
    Bara, I.
    Chaft, J.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S233 - S234
  • [2] Updated Efficacy/Safety Data From the Phase 2 NP28761 Study of Alectinib in ALK plus NSCLC
    Shaw, Alice
    West, Howard
    Socinski, Mark A.
    Ou, Ignatius
    Gandhi, Leena
    Gadgeel, Shirish
    Belani, Chandra P.
    Shirai, Keisuke
    Bazhenova, Lyudmila
    Santos, Edgardo
    Riely, Gregory J.
    Chiappori, Alberto
    Cetnar, Jeremy
    Mekhail, Tarek
    Chao, Bo
    Borghaei, Hossein
    Gold, Kathryn A.
    Johannsdottir, Hrefna
    Ruf, Thorsten
    Boisserie, Frederic
    Henschel, Volkmar
    Zeaiter, Ali
    Camidge, Ross
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S237 - S238
  • [3] Targeted adjuvant: First Data on Alectinib in Patients with operable ALK plus NSCLC
    不详
    ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 (05)
  • [4] The efficacy and safety of alectinib in the treatment of ALK plus NSCLC: a systematic review and meta-analysis
    Fan, Junsheng
    Xia, Zengfei
    Zhang, Xiaoli
    Chen, Yuqing
    Qian, Ruolan
    Liu, Sihan
    You, Danming
    Zhang, Jian
    Luo, Peng
    ONCOTARGETS AND THERAPY, 2018, 11 : 1105 - 1115
  • [5] ALINA: Efficacy and safety of adjuvant alectinib versus chemotherapy in patients with early-stage ALK plus non-small cell lung cancer (NSCLC)
    Solomon, B. J.
    Ahn, J. S.
    Dziadziuszko, R.
    Barlesi, F.
    Nishio, M.
    Lee, D. H.
    Lee, J. S.
    Zhong, W. Z.
    Horinouchi, H.
    Mao, W.
    Hochmair, M. J.
    De Marinis, F.
    Migliorino, M. R.
    Bondarenko, I.
    Lohmann, T. O.
    Xu, T.
    Gavaldon, A. Cardona
    Bordogna, W.
    Ruf, T.
    Wu, Y. L.
    ANNALS OF ONCOLOGY, 2023, 34 : S1295 - S1296
  • [6] ALINA: efficacy and safety of adjuvant alectinib versus chemotherapy in patients with early-stage ALK plus non-small cell lung cancer (NSCLC)
    Shah, Rajiv
    Solomon, Benjamin J.
    Ahn, Jin Seok
    Dziadziuszko, Rafal
    Barlesi, Fabrice
    Nishio, Makoto
    Lee, Dae Ho
    Lee, Jong-Seok
    Zhong, Wenzhao
    Horinouchi, Hidehito
    Mao, Weimin
    Hochmair, Maximilian
    de Marinis, Filippo
    Migliorino, Maria Rita
    Bondarenko, Igor
    Lohmann, Tania Ochi
    Xu, Tingting
    Cardona, Andres
    Bordogna, Walter
    Ruf, Thorsten
    Wu, Yi-Long
    ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 : 243 - 244
  • [7] Phase 3 ALUR Study of Alectinib in Pretreated ALK plus NSCLC: Final Efficacy, Safety and Targeted Genomic Sequencing Analyses
    Wolf, J.
    Helland, A.
    Oh, I.
    Migliorino, M. R.
    Dziadziuszko, R.
    De Castro Carpeno, J.
    Mazieres, J.
    Griesinger, F.
    Chlistalla, M.
    Cardona, A.
    Ruf, T.
    Trunzer, K.
    Smoljanovic, V.
    Novello, S.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S210 - S210
  • [8] Updated Data from JP28927 Study of Alectinib in ALK plus NSCLC Patients with or without History of ALK Inhibitor Treatment
    Hotta, Katsuyuki
    Hida, Toyoaki
    Nakagawa, Kazuhiko
    Seto, Takashi
    Satouchi, Miyako
    Nishio, Makoto
    Murakami, Haruyasu
    Ohe, Yuichiro
    Takeda, Koji
    Yoshimoto, Takuya
    Tanaka, Tomohiro
    Tamura, Tomohide
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S648 - S648
  • [9] Efficacy and safety of dose-escalated alectinib in patients with metastatic ALK-positive NSCLC and CNS relapse on standard dose alectinib
    Cheung, Justin Matthew
    Kang, Jiyoon
    Yeap, Beow Y.
    Peterson, Jenn
    Do, Andrew
    Digumarthy, Subba R.
    Gainor, Justin F.
    Lin, Jessica Jiyeong
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [10] Efficacy and Safety of Dose-Escalated Alectinib in Patients with Metastatic ALK-positive NSCLC and CNS Relapse on Standard Dose Alectinib
    Cheung, Justin M.
    Kang, Jiyoon
    Yeap, Beow Y.
    Peterson, Jennifer L.
    Do, Andrew
    Gainor, Justin F.
    Digumarthy, Subba R.
    Lin, Jessica J.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (07) : E31 - E31
12345